Compare · MRNA vs SOPH
MRNA vs SOPH
Side-by-side comparison of Moderna Inc. (MRNA) and SOPHiA GENETICS SA (SOPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and SOPH operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $24.20B, about 64.5x SOPH ($375.5M).
- Over the past year, MRNA is up 127.4% and SOPH is up 64.1% - MRNA leads by 63.4 points.
- SOPH has been more active in the news (23 items in the past 4 weeks vs 14 for MRNA).
- MRNA has more recent analyst coverage (25 ratings vs 13 for SOPH).
- Company
- Moderna Inc.
- SOPHiA GENETICS SA
- Price
- $60.95+2.70%
- $5.25-2.42%
- Market cap
- $24.20B
- $375.5M
- 1M return
- +28.98%
- +4.17%
- 1Y return
- +127.44%
- +64.06%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2021
- News (4w)
- 14
- 23
- Recent ratings
- 25
- 13
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
SOPHiA GENETICS SA
Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.
Latest MRNA
- Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine
- SEC Form 144 filed by Moderna Inc.
- President Hoge Stephen sold $2,739,870 worth of shares (53,336 units at $51.37) as part of a pre-agreed trading plan and exercised 53,336 shares at a strike of $19.15 (SEC Form 4)
- Moderna to Host Investor Event - Science Day
- Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028
- Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
- Chief Legal Officer Klinger Shannon Thyme exercised 15,269 shares at a strike of $7.04, sold $173,550 worth of shares (3,471 units at $50.00) as part of a pre-agreed trading plan and covered exercise/tax liability with 5,705 shares, increasing direct ownership by 9% to 73,561 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Mock James M converted options into 11,798 shares and covered exercise/tax liability with 5,705 shares, increasing direct ownership by 10% to 65,687 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Mock James M converted options into 2,475 shares and covered exercise/tax liability with 1,197 shares, increasing direct ownership by 2% to 59,594 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 2,165 shares and covered exercise/tax liability with 1,047 shares, increasing direct ownership by 2% to 67,468 units (SEC Form 4) (tax withholding)
Latest SOPH
- Chief Financial Officer Cardoza George sold $4,164 worth of Ordinary Shares (774 units at $5.38) as part of a pre-agreed trading plan, decreasing direct ownership by 0.25% to 310,684 units (SEC Form 4) to satisfy withholding obligation
- President Muken Ross sold $2,270 worth of Ordinary Shares (422 units at $5.38) as part of a pre-agreed trading plan, decreasing direct ownership by 0.06% to 680,489 units (SEC Form 4) (for withholding tax)
- SEC Form 144 filed by SOPHiA GENETICS SA
- Director Cox Troy was granted 19,724 units of Ordinary Shares, increasing direct ownership by 6% to 328,743 units (SEC Form 4)
- Director Ossipow Vincent was granted 19,724 units of Ordinary Shares, increasing direct ownership by 4% to 522,860 units (SEC Form 4)
- Director Hibbs Kathy L was granted 19,724 units of Ordinary Shares, increasing direct ownership by 22% to 109,492 units (SEC Form 4)
- Director Hirsch Didier was granted 19,724 units of Ordinary Shares, increasing direct ownership by 9% to 240,220 units (SEC Form 4)
- Director Cossery Jean-Michel was granted 19,724 units of Ordinary Shares, increasing direct ownership by 11% to 206,212 units (SEC Form 4)
- SEC Form 6-K filed by SOPHiA GENETICS SA
- SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting